top of page
Publications
Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study
2022
Chest
Henriette Zweijpfenning SM, Chiron R, Essink S et al.; NTM-NET
DIO:
10.1016/j.chest.2022.01.015
Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation
2020
Respir Med
Schildkraut JA, Gallagher J, Morimoto K et al.; NTM-NET
DIO:
10.1016/j.rmed.2020.106164
Non-tuberculous mycobacterial lung disease in patients with bronchiectasis: perceived risk, severity and guideline adherence in a European physician survey
2020
BMJ Open Respir Res
Wagner D, van Ingen J, van der Laan R et al.; NTM-NET
DIO:
10.1136/bmjresp-2019-000498
Clofazimine does not lead to significant QT interval prolongation: a multicentre study
2018
Eur Respir J
Zweijpfenning SMH, van Groningen H, van Ingen J et al.; NTM-NET
DIO:
10.1183/13993003.01386-2018
Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement
2018
Eur Respir J
van Ingen J, Aksamit T, Andrejak C et al.; NTM-NET
DIO:
10.1183/13993003.00170-2018
Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases
2017
Eur Respir J
van Ingen J, Wagner D, Gallagher J et al.; NTM-NET
DIO:
10.1183/13993003.01855-2016
Nontuberculous Mycobacteria Network European Trials Group. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study.
2013
Eur Respir J.
Hoefsloot W, van Ingen J, Andrejak C et al.; NTM-NET
DIO:
10.1183/09031936.00149212.
bottom of page